Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01543152 · ClinicalTrials.gov registry record · Phase 1
Dose Escalation Study of Cyclophosphamide in HIV-Infected Subjects on HAART Receiving SB-728-T
A Phase 1 study, sponsored by Sangamo Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 26
- Enrollment target
NCT01543152 is a Phase 1 study that has completed, run by Sangamo Therapeutics. The registered enrollment target is 26 participants.
The verdict
NCT01543152, a Phase 1 study, has completed, sponsored by Sangamo Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 26 participants
- Enrollment target
Study Summary
The purpose of the study is to evaluate the safety, tolerability and effect on HIV viral load, of escalating doses of cyclophosphamide administered 1 day prior to SB-728-T infusion.
Interventions
- GENETIC SB-728-T
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2011-12 |
| Est. Completion | 2017-07-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01543152
The ClinicalTrials.gov registry entry for NCT01543152 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sangamo Therapeutics, which has 25 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which SB-728-T is the first listed.
NCT01543152 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01543152 about?
NCT01543152 is a clinical study titled "Dose Escalation Study of Cyclophosphamide in HIV-Infected Subjects on HAART Receiving SB-728-T". The purpose of the study is to evaluate the safety, tolerability and effect on HIV viral load, of escalating doses of cyclophosphamide administered 1 day prior to SB-728-T infusion.
What is the current status of trial NCT01543152?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 26 participants. The study started on 2011-12. Estimated completion is 2017-07-07.
What interventions are being tested in trial NCT01543152?
The interventions under investigation include: SB-728-T (GENETIC).
Who is sponsoring clinical trial NCT01543152?
This trial is sponsored by Sangamo Therapeutics, which has 25 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.